- Home
- SCLX vs CEE Comparison
SCLX vs CEE Comparison
Compare SCLX & CEE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCLX
- CEE
- Stock Information
- Founded
- SCLX 2011
- CEE 1990
- Country
- SCLX United States
- CEE Germany
- Employees
- SCLX N/A
- CEE N/A
- Industry
- SCLX Biotechnology: Pharmaceutical Preparations
- CEE Finance Companies
- Sector
- SCLX Health Care
- CEE Finance
- Exchange
- SCLX Nasdaq
- CEE Nasdaq
- Market Cap
- SCLX 81.7M
- CEE 79.2M
- IPO Year
- SCLX N/A
- CEE N/A
- Fundamental
- Price
- SCLX $0.48
- CEE $11.65
- Analyst Decision
- SCLX Strong Buy
- CEE
- Analyst Count
- SCLX 3
- CEE 0
- Target Price
- SCLX $11.33
- CEE N/A
- AVG Volume (30 Days)
- SCLX 184.3K
- CEE 22.0K
- Earning Date
- SCLX 12-24-2024
- CEE 01-01-0001
- Dividend Yield
- SCLX N/A
- CEE 3.86%
- EPS Growth
- SCLX N/A
- CEE N/A
- EPS
- SCLX N/A
- CEE N/A
- Revenue
- SCLX $50,833,000.00
- CEE N/A
- Revenue This Year
- SCLX $32.77
- CEE N/A
- Revenue Next Year
- SCLX $50.71
- CEE N/A
- P/E Ratio
- SCLX N/A
- CEE N/A
- Revenue Growth
- SCLX 9.41
- CEE N/A
- 52 Week Low
- SCLX $0.46
- CEE $7.80
- 52 Week High
- SCLX $2.63
- CEE $10.32
- Technical
- Relative Strength Index (RSI)
- SCLX 33.34
- CEE 48.85
- Support Level
- SCLX $0.48
- CEE $11.56
- Resistance Level
- SCLX $0.54
- CEE $12.26
- Average True Range (ATR)
- SCLX 0.06
- CEE 0.38
- MACD
- SCLX -0.00
- CEE -0.08
- Stochastic Oscillator
- SCLX 4.53
- CEE 44.03
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
About CEE The Central and Eastern Europe Fund Inc. (The)
CENTRAL & EASTERN EUROPE FUND, INC. is a closed-end management investment company. The Fund's objective is to seek long-term capital appreciation. It invests in the equity or equity-linked securities of issuers domiciled in Central and Eastern Europe.